Natco Pharma secures VAI status from the USFDA after four observations at its Visakhapatnam finished dosage formulations manufacturing facility.
Atopic dermatitis treatment faces a setback as Celldex discontinues barzolvolimab development following disappointing Phase 2 results.
The US Food and Drug Administration (FDA) has approved Sanofi’s Infilbray (venglustat), the first drug specifically designed to treat neurological symptoms of Type 3 Gaucher disease.
The narcolepsy drug Orzeyful has entered the US market, giving Takeda a new commercial opportunity in sleep disorder treatment following final regulatory clearance.
Amgen's experimental drug dazodalibep has delivered positive Phase 3 results, offering new possibilities for Sjogren's disease treatment.
Divi's Labs bets on peptide growth with a Rs 2,000 crore expansion to strengthen innovative pharmaceutical manufacturing and meet customer demand.
Two major heart trials from Novartis and Novo Nordisk have delivered a sobering message for cardiovascular drug development.
Evommune's USD 1.1 billion Hinova deal advances a VAV1 degrader targeting autoimmune diseases, putting protein degradation technology and rheumatoid arthritis development in focus.
Nurix loses a potential USD 455 million milestone opportunity after Sanofi discontinues its STAT6 degrader programme, raising questions about targeted protein degradation in autoimmune drug development.
Cerus' Phase 3 success advances Blood Safety research, raising questions about pathogen reduction's potential role in strengthening India's blood transfusion infrastructure and preparedness.